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TGF-betaHepatocellular carcinoma (HCC) cells with amesenchymal phenotype show an asymmetric subcellular distribu-
tion of the chemokine receptor CXCR4,which is required for cellmigration and invasion. In thisworkwe examine
the mechanisms that regulate the intracellular trafﬁcking of CXCR4 in HCC cells. Results indicate that HCC cells
present CXCR4 at the cell surface, but most of this protein is in endomembranes colocalizing with markers of
the Golgi apparatus and recycling endosomes. The presence of high protein levels of CXCR4 present at the cell
surface correlates with a mesenchymal-like phenotype and a high autocrine activation of the Transforming
Growth Factor-beta (TGF-β) pathway. CXCR4 trafﬁcs along the Golgi/exocyst/plasma membrane pathway and
requires EXOC4 (Sec8) component of the exocyst complex. HCC cells use distinct mechanisms for the CXCR4
internalization such as dynamin-dependent endocytosis and macropinocytosis. Regardless of the endocytic
mechanisms, colocalization of CXCR4 and Rab11 is observed, which could be involved not only in receptor
recycling but also in its post-Golgi transport. In summary, this work highlights membrane trafﬁcking pathways
whose pharmacological targeting could subsequently result in the inactivation of one of the main guiding mech-
anisms used by metastatic cells to colonize secondary organs and tissues.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
CXCR4 is a G-protein coupled chemokine receptor originally detect-
ed and cloned from leukocytes [1]. CXCR4 was identiﬁed as the co-
receptor for HIV entry [2,3], and subsequently characterized as the re-
ceptor for the chemotactic cytokine stromal derived factor-1-alpha
(SDF-1α/CXCL12) that controlled cell migration to inﬂammatory foci
[4,5]. Although CXCR4 function was initially thought to be restricted to
the immune system, early reports also showed an increased expression
of CXCR4 in cancer cells [6], unveiling the potential of CXCR4 in control-
ling themigration ofmetastatic cells. Recent works have evidenced that
the CXCR4/SDF-1α axis does not only play a role in chemotacticBIS,bisindolylmaleimide II;BFA,
nﬂuorescentprotein;EGFR,epi-
; HCC, hepatocellular carcinoma
4; SDF-1α, stromal cell-derived
ch Institute (IDIBELL), Gran Via
ain. Tel.: +34 932 60 78 28;guidance of migrating cells towards metastatic niches, but also in
tumor initiation and progression, angiogenesis, metastasis, migratory
potential and tumor cell survival [7]. Furthermore, overexpression of
CXCR4 has been detected in tumor progenitor/cancer stem cells in dif-
ferent tumors [8–11]. For this reason, there is a recent interest in neu-
tralizing the CXCR4/SDF-1α axis to potentially reduce metastatic
colonies [12].
Very little is known about how CXCR4 reaches the plasma
membrane and how it is regulated. CXCR4 is an N-glycosylated protein
[13] and thereforemust follow the secretory pathway crossing theGolgi
apparatus, but its subsequent post-Golgi egress and trafﬁcking is almost
unknown. It has been reported that membrane expression of CXCR4 in
MT-4 T-lymphocytes requires a functional CD63 tetraspanin, since
expression of an N-terminal deletion mutant of CD63 results in the
mislocalization of CXCR4 to the endosomal/lysosomal compartment
[14]. Rab GTPases Rab2, Rab6 and Rab8 have been also implicated in
the anterograde trafﬁc of CXCR4 to the plasma membrane [15,16]. On
the other hand, membrane CXCR4 in T-lymphocytes undergoes a slow
and constitutive (tonic) internalization process (approx. 1% of surface
CXCR4/min) through clathrin-mediated endocytic pathway [17]. The
subsequent incubation with SDF-1α induced a rapid entry of the
receptor (50% in 5 min), which required the dileucine motif IL329 and
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C-terminal domain [18–20].
As with other chemokine receptors, internalized CXCR4 trafﬁcs
through endosomal compartments either to lysosomes (degradative
pathway) or to be recycled back to the plasma membrane [21]. After
interacting with ligand, CXCR4 is rapidly ubiquitinated by the E3 ubiq-
uitin ligase AIP4 [22], and a further complex with arrestin-2 targets it
to the degradative pathway [23]. On the other hand, in hematopoietic
progenitor cells, internalized CXCR4 colocalizes with EEA1+, Rab4+,
Rab5+, or Rab11+ compartments [24] in an actin-dependent manner
[25] indicating the participation of endosomal recycling pathway.
CXCR4 is up-regulated in human hepatocellular carcinoma (HCC) [26,
27] correlatingwith progression of the disease [28] andmetastatic poten-
tial [29]. Its ligand SDF-1α (CXCL12) stimulates human hepatoma cell
growth, migration and invasion [27]. We previously reported that the
transforming growth factor beta (TGF-β) regulates the expression and
targeting of CXCR4 to the plasma membrane at the presumptive migra-
tion front of the tumor cells [30]. We also demonstrated a cross-talk be-
tween TGF-β and CXCR4 in human liver tumors and HCC cell lines, so
that autocrine TGF-β stimulation results in a shift towards amesenchymal
phenotype that correlates with CXCR4 upregulation and its asymmetric
distribution, which is required for cell migration [31]. Since little is
known about the intracellular trafﬁcking of CXCR4 in liver tumor cells
we here have examined themechanisms that regulate both the secretion
and endocytosis of this chemokine receptor in cultured human HCC cells.
2. Material and methods
2.1. Antibodies and reagents
For the development of this work, the following antibodies and
reagents were used: anti-AP1, anti-AP2, anti-Rab4A and anti β-COP
from Sigma-Aldrich (St Louis, MO, USA), anti-CXCR4 [CD184] from
Abcam (Cambridge, UK), anti-EXOC4 (Sec8), anti-Rab11, anti-CXCR4APC,
anti-CD3APC, anti-clathrin heavy chain (CHC), anti-Golgin97, anti-
GM130, and anti-M6PR were all from Pharmingen-BD (San Jose, CA,
USA), anti-Rab5A and anti-EGFRPE were from Santa Cruz Biotechnology
(Dallas, TX, USA). Alexa 488, 555, 567 or 647-conjugated secondary
antibodies, Alexa 568-conjugated Phalloidin, tetramethylrhodamine-
conjugated transferrin and ProLong Gold Antifade were from Molecular
Probes–Life Technologies (Eugene, OR, USA). HRP-conjugated IgGs were
from Dako (Glostrup, DK). SDF-1α, AMD3100, dimethylamiloride
(DMA), methyl-β-cyclodextrin, brefeldin A, bisindolylmaleimide II and
water-soluble cholesterol were from Sigma-Aldrich, DRAQ5 was from
Biostatus (Shepshed, Leicestershire, UK), TGF-β and dynasore were
obtained from Calbiochem (Darmstadt, Germany). DMEM and MEM
culture media, heat inactivated fetal bovine serum (FBS) and sodium
pyruvate were from Gibco-Life Technologies (Eugene, OR, USA), the
penicillin–streptomycin mix was from Biological Industries (Kibbutz
Beit Haemek, Israel), propidium iodide (in solution), paraformaldehyde
(PFA), Triton X-100, bovine serum albumin (BSA) and general laboratory
reagents were from Sigma-Aldrich (St Louis, MO, USA). Human CXCR4-
EGFP was a kind gift of Dr. Peter van Hordjik (Sanquin Blood Supply,
Amsterdam, The Netherlands), This clone encodes a copy of human
CXCR4 fused in-frame with the EGFP reporter (pEGFP-N1), so that a
Cterminal fusion is generated that does not interferewith ligand binding.
Clones encoding a wild type and a dominant negative form of rat EXOC4
(EXOC4wt, EXOC4S32A) were kindly obtained fromDr. GE Lienhard (Dept.
of Biochemistry, Dartmouth Med. Sch., Hanover, NH, USA).
2.2. Cell culture and transfections
PLC/PRF/5 and Hep3B cells were obtained from the European Collec-
tion of Cell Cultures (ECACC). PLC/PRF/5 cells were cultured in DMEM
and Hep3B in MEM. All media were supplemented with 10% FBS, 50 U/
mL penicillin, 50 μg/mL streptomycin, 1% (v/v) sodium pyruvate. Cellswere grown in a humidiﬁed atmosphere of 37 °C, 5% CO2. Cells were
magneto-transfected with the different plasmids studied in this work by
using the MATra-A reagent (IBA GmbH, Germany) following the
manufacturer's instructions. PLC/PRF/5 and Hep3B expressing a stable
sh-RNA that targeted speciﬁcally the TGF-β receptor I (TβRI), were previ-
ously obtained in our laboratory [31] andwere cultured as theirwild-type
counterparts.2.3. Cell treatments
In this work, cells were treated with SDF-1α, with its antagonist
AMD3100, with the endocytosis inhibitors: dynasore, methyl-β-
cyclodextrin (MβC) and dimethylameloride (DMA), with brefeldin A,
bisindolylmaleimide II or water-soluble cholesterol, either alone or in
combination. Prior to be treated with SDF-1α or with AMD3100, cells
were serum-starved overnight, the culture medium was replaced by a
new medium that included 100 ng/mL SDF-1α or 1 μg/mL AMD3100
and the cells were incubated in a humidiﬁed atmosphere of 37 °C, 5%
CO2 for 8 h. To overcome SDF-1α- induced internalization of CXCR4,
80 μM dynasore, 2.5 μMMβC or 100 μMDMAwas added to the culture
medium30min before addition of SDF-1α. For experiments of transfer-
rin internalization, as a control of endocytosis inhibitor efﬁciency, cells
were pre-treated with 80 μM dynasore for 30 min. Then, a transferrin-
rhodamine conjugate was added to the cultures at 20 μg/mL and cells
left to internalize the label for the stated times, before being analyzed
by immunocytochemistry. Brefeldin A was used at 10 μg/mL for 3 h
and bisindolylmaleimide II was used at 10 μM for 8 h, on overnight
serum starved cells. 1 mM water-soluble cholesterol was used for 1 h
on cells previously treated with MβC and prior to the incubation with
SDF-1α (see above).2.4. Flow cytometric analysis
Cells were detached and centrifuged at 1200 rpm for 5 min. For anal-
ysis at cell surface CXCR4 (sCXCR4), cells were resuspended with 1% BSA
in PBS and incubatedwith the anti-CXCR4APC antibody for 30min at 4 °C.
After washing with PBS and following centrifugation, cells were resus-
pended in PBS and cell ﬂuorescence measured in a Beckman-Coulter
Gallios ﬂow cytometer. Data were analyzed with the Kaluza software
(Beckman Coulter Inc., Brea, CA, USA). For analysis of the total cellular
CXCR4, cells were ﬁxed with 4% paraformaldehyde (PFA) in PBS for
15 min, centrifuged and permeabilized with 1% Triton in PBS for 3 min.
After centrifugation, cells were resuspended in 1% BSA in PBS and
incubated with CXCR4 antibody as above described for sCXCR4 analysis.2.5. Immunocytochemical analysis, epiﬂuorescence and confocal microscopy
Cells were seeded on coverslips coated with 2% bovine gelatin, ﬁxed
with 4% paraformaldehyde, permeabilized with 1% Triton X-100 in PBS
(20 min, RT), washed with PBS, blocked with 1% BSA, 0.2% Triton X-100
in PBS (30min, RT) and incubated overnight with the primary antibody
in 1% BSA in PBS at 4 ° C. After extensive washing, cells were incubated
with the secondary antibody, in 1% BSA in PBS (1 h, RT), washed and in-
cubated with 0.1% DRAQ5 in PBS for 5 min. Coverslides were mounted
using ProLong Gold Antifade. Epiﬂuorescence microscopy analysis was
performed in a Nikon Eclipse 80i microscope provided with a Pan
Fluor 60 × 0.5–1.25 oil objective. For confocal imaging, we used a
Leica TSC SL spectral confocal microscope, with argon (488 nm) and
HeNe (543 nm) lasers, and a HCX PL Apo 63 × 1.40 oil objective. For
each experiment, at least 10 different ﬁelds were studied using the
LCS Lite software (Leica) and representative images are shown. The pro-
ﬁling of pixel intensity was performed by using the “quantiﬁcation”
module of the LCS Lite software (Leica).
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Cells at 70% conﬂuence were transiently transfected with 100 nM
(EXOC4) or 50 nM (clathrin heavy chain, CHC) siRNAs for 8 h using
the TransIT-siQuest reagent (Mirus, Madison, WI, USA) according to
the manufacturer's recommendations. siRNA oligonucleotides were
obtained from Sigma-Genosys. Sequences were as follows:
unsilencing/control: 5′-GUAAGACACGACUUAUCC-3′
human EXOC4#1: 5′-ACUCUGUGGUCCUGGGAUA-3′
human CHC: 5′-GGGAAGAAUUGGUGAAGUA-3′.
2.7. Western blotting detection of EXOC4
Cells that had to be submitted to Western blotting were lysed as
previously described [32] prior to be boiled and loaded to standard
10% or 12% SDS-PAGE gels. SubsequentWestern blottingwasperformed
as described [33], using an anti-EXOC4 speciﬁc antibody. Anti-β-actin
was used as a loading control.
2.8. Statistical analysis
Data are expressed as themean± S.D. of at least three experiments.
Differences between groupswere compared using Student's t-test (when
comparing two groups) or one-way ANOVA with Tukey's multiple com-
parison test (when comparing more than two groups and considering
one independent variable). Differences were considered statistically
signiﬁcant at p b 0.05.
3. Results
We here report the mechanisms involved in the intracellular
trafﬁcking of CXCR4 using two human HCC cell lines: PLC/PRF/5 and
Hep3B. PLC/PRF/5 cells show an epithelial-like phenotype and low
expression of TGF-β, concomitant with moderate protein levels of
CXCR4. In contrast, Hep3B cells show a mixed epithelial–mesenchy-
mal-like phenotype and a high autocrine production of TGF-β, express-
ing increased levels of CXCR4 that is asymmetrically distributed in the
cell [31].
3.1. Subcellular localization of CXCR4 in human HCC cell lines
We ﬁrst analyzed the expression of CXCR4 in PLC/PRF/5 and Hep3B
cells by ﬂow cytometry, using an APC-labeled, anti-CXCR4-speciﬁc
antibody. Fig. 1A shows that CXCR4 was mostly found in internal com-
partments in PLC/PRF/5 cells. Only a fraction of the cells (over 60%)
was positive for CXCR4 at the cell surface (sCXCR4, Fig. 1A, central right
panel), and levels were much lower than those found in permeabilized
cells (Fig. 1A, central left panel, and compare ﬂuorescence intensities of
the overlay plots of Fig. 1A, lower panels). These low levels of CXCR4 in
the plasma membrane were not due to a possible inability of the
APC-conjugated anti-CXCR4 antibody to recognize membrane CXCR4
since it was able to detect the membrane expression of the receptor in
the Jurkat human T-leukemia cells that we used as positive control
(see Suppl. Fig. S1). Conversely, Hep3B cells were strongly positive for
sCXCR4 (Fig. 1B, central right panel), although levels were also lower
than those found in the permeabilized cells, indicating that CXCR4 is
located in intracellular compartments too (Fig. 1B, central left panel,
and compare ﬂuorescence intensities of the overlay plots of Fig. 1B,
lower panels). The ﬂuorescence plot of Hep3B cells for sCXCR4 showed
a wide peak, which indicates high variability in the sCXCR4 levels/cell
(Fig. 1B, central right panel).
The subcellular distribution of endogenous CXCR4 in PLC/PRF/5
and Hep3B cells showed the presence of CXCR4 at the cell surface,
particularly in the intercellular junctions, as well as in intracellular com-
partments (Fig. 1C and D, left panels, arrows and arrowheads,respectively). After transfection of both PLC/PRF/5 and Hep3B cells with
a CXCR4–EGFP construction, EGFP ﬂuorescence was also located in the
intercellular junctions as well as in perinuclear vesicles (Fig. 1C and D,
right panels, arrows and arrowheads, respectively). In order to
know whether the intracellular localization of CXCR4 could be only the
consequence of CXCR4 trafﬁcking due, for example, to autocrine SDF-1α
production or heterologous regulation of the receptor by PKC, we tested
the effect of CXCR4 antagonists (AMD3100) or PKC inhibitors
(bisindolylmaleimide II) on the presence of CXCR4 at the cell surface
(Suppl. Fig. S2). None of these inhibitors had any signiﬁcant effect,
which indicates that these HCC cells maintain part of the CXCR4 in intra-
cellular compartments by mechanisms that may be independent of its
ligand-mediated intracellular trafﬁcking.
Expression of CXCR4 is dependent on the autocrine production of
TGF-β in HCC cells [31]. Here we show that targeting knock-down of
the TGF-β receptor I (TβRI) in PLC/PRF/5 cells produced a slight (non-sig-
niﬁcant) reduction of sCXCR4 (Suppl. Fig. S3), correlatingwith theirmod-
est autocrine production of TGF-β [31]. In contrast, in Hep3B cells, which
produce TGF-β in an autocrine way [31], targeting knock-down of the
TβRI produced a decrease in the percentage of cells with high sCXCR4
levels (60% decrease in the sCXCR4 levels in the silenced TβRI cells versus
control cells, p b 0.05) (Suppl. Fig. S3). The use of these two different HCC
cell lines in the study of CXCR4 trafﬁcking is interesting because they rep-
resent two different epithelial–mesenchymal HCC cell models.
3.2. Intracellular CXCR4 transport to the plasma membrane correlates with
a Golgi-exocyst axis
In the aforementioned experiments, we analyzed the subcellular
distribution of CXCR4 by using an anti-CXCR4 speciﬁc antibody and
the CXCR4–EGFP chimera. Since both methods gave similar results, we
next continued using CXCR4–EGFP because it provides enhanced
sensitivity and unspeciﬁc antibody cross-reactions are avoided.
We next transfected PLC/PRF/5 and Hep3B cells with the CXCR4–
EGFP construct and studied its co-localizationwith a number of secreto-
ry and endocytic endomembrane markers. CXCR4–EGFP colocalized
with golgin97, a marker of the trans-Golgi network, and with AP1
adaptin complex, marker of the secretory route, in both HCC cell lines
(Fig. 2, arrows). CXCR4–EGFP also colocalizes with coatomer COPI
complex (β-COP), GM130 (cis-Golgi marker), and M6PR (marker of
the trans-Golgi network as well as of endosomal bodies trafﬁcking to
and from late endosomes) (Suppl. Fig. S4) Therefore, CXCR4 widely
colocalizes with markers of the secretory and endocytic compartments.
3.3. CXCR4 transport to the plasmamembrane requires a functional exocyst
complex
Next we examined the contribution of the exocyst complex in the
transport of CXCR4 to the cell surface. We ﬁrst analyzed the subcellular
distribution of the exocyst complex component 4 (EXOC4) in PLC/PRF/5
and Hep3B cells. Anti-EXOC4 antibody stained a region of the plasma
membrane where adjacent cells are in contact. Fig. 3A shows the pres-
ence of CXCR4–EGFP (upper left panel, arrows) and EXOC4 (lower left
panel, arrows) in the cell-to-cell junction. The right panels show the
co-localization of both signals (upper), as well as the three orthogonal
sections that show that both EXOC4 and CXCR4–EGFP targeted to the
lateral membrane of the cells (Fig. 3A, lower right panels, arrowheads).
To investigatewhether there is a functional link between CXCR4 and
the exocyst complex, we targeted knock-down EXOC4 in PLC/PRF/5
cells using speciﬁc siRNAs (Fig. 3B), and analyzed sCXCR4 by ﬂow
cytometry. PLC/PRF/5 cells treated with EXOC4 siRNA showed lower
levels of sCXCR4 (Fig. 3C, left; quantitative analysis on right). The
dependence on EXOC4 for the transport of CXCR4 to the plasma mem-
branewas further conﬁrmed using CXCR4–EGFP and the dominant nega-
tive form of rat EXOC4 ([EXOC4S32A]) [34]. Cells that expressed the
dominant negative mutant showed a much dispersed and cytoplasmic
Fig. 1.Analysis of the localization of CXCR4 in theHCC cell lines PLC/PRF/5 andHep3B. Effect of targeting knock-down the TβRI. A:ﬂow cytometric analysis of cellular CXCR4 content in perme-
abilized PLC/PRF/5 cells (left plots) and cell surface CXCR4 (sCXCR4) in live PLC/PRF/5 (right plots). Upper plots show the pattern displayed by unlabeled cells as control, central plots display
cells labeled with an anti-CXCR4APC antibody, and the lower plots show the merge of the two signals. B: as in A except that Hep3B cells were used in the analysis. C and D: left. Confocal mi-
croscopy analysis of PLC/PRF/5 (C) andHep3B (D) cells labeledwith anti-CXCR4APC antibody. Amax. projection of two consecutive confocal sections is shown. Right: confocalmicroscopy anal-
ysis of PLC/PRF/5 (C) and Hep3B (D) cells expressing a CXCR4-EGFP construct. A single confocal section at a medium focal plane is shown in PLC/PRF/5 cells. A max. projection of two
consecutive confocal sections at the medium focal plane is shown in Hep3B cells. Scale bars are 20 μm. Arrows indicate cell surface CXCR4, and arrowheads internal CXCR4 deposits.
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displayed by cells expressing thewild type formof EXOC4 (Suppl. Fig. S5).
We also studied the subcellular distribution of EXOC4 and CXCR4–
EGFP in theHep3B cells. CXCR4–EGFP and EXOC4 colocalized in discrete
regions of the plasma membrane (Fig. 4A, arrows and arrowheads). In-
terestingly, numerous cytoplasmic vesicles were colabeled for EXOC4
and CXCR4–EGFP, mainly at the tip of growing projections of Hep3B
cells (Fig. 4A, lower right insert panel, yellow arrow). Furthermore,
like in PLC/PRF/5 cells, CXCR4–EGFP and EXOC4 were also visualized
at cell-to-cell junctions (Fig. 4B, arrows).3.4. SDF-1α induces the internalization of CXCR4
The membrane levels of chemokine receptors result from the ratio
balance between the export of its receptor and its internalization after
ligand binding or spontaneous tonic endocytosis. We next investigated
the mechanisms controlling CXCR4 internalization, as well as their
impact on themaintenance of receptor levels in themembrane by stim-
ulating HCC cells with the speciﬁc CXCR4 ligand SDF-1α. Thus we ﬁrst
analyzed by ﬂow cytometry the cell surface levels of CXCR4 (Fig. 5).
SDF-1α induced the internalization of CXCR4 in PLC/PRF/5 cells (40%
Fig. 2. CXCR4 trafﬁcs to the plasmamembrane following the Golgi-AP1 axis. Representative confocal images of PLC/PRF/5 cells expressing the CXCR4–EGFP chimera (left panel), their staining
with an anti-golgin97 antibody (A, central panel) or an anti-AP1 antibody (B, central panel), and the co-localization of both signals (yellowpixels at the respective right panels). Arrowspoint to
the colocalization of EGFP–CXCR4 with the Golgi marker or the AP1–adaptin complex. Arrowhead points to EGFP–CXCR4 at a cell-to-cell junction. In the central and right panels several
untransfected cells are also shown. A max. projection of 20 consecutive confocal sections is shown for golgin97 in PLC/PRF/5 cells; a single confocal section at the medium focal plane is
shown for AP-1 in PLC/PRF/5. Three consecutive confocal sections at the medium focal plan are shown in Hep3B cells for both golgin97 and AP-1. Scale bar is 16 μm in A and 20 μm in B.
1209E.B. Cepeda et al. / Biochimica et Biophysica Acta 1853 (2015) 1205–1218decrease in sCXCR4 ﬂuorescence after 8 h of incubationwith the ligand:
Fig. 5A, upper panels; quantiﬁcation in Fig. 5B). Hep3B cells showed a
similar loss of signal, with a reduction of 50% of sCXCR4 ﬂuorescence
after SDF-1α treatment (Fig. 5C, upper panels, quantiﬁcation in Fig. 5D).
To investigate the contribution of different endocyticmechanisms in
the CXCR4 internalization, cells were treated with two endocytosis
inhibitors: (i) dynasore, which inhibits clathrin as well as caveolin-
mediated internalization by inhibiting the activity of dynamins I and II
[35], and (ii) MβC, which disrupts the integrity of the lipid rafts and
inhibits caveolin-dependent internalization of membrane receptors.
PLC/PRF/5 and Hep3B cells were treated with dynasore or MβC for
30 min before adding SDF-1α, and sCXCR4 levels were analyzed by
ﬂow cytometry. In PLC/PRF/5 cells, both dynasore and MβC were
shown to prevent the SDF-1α-induced internalization of CXCR4, whichsuggests that CXCR4 internalization proceeded via clathrin and/or
caveolin-mediated endocytosis (Fig. 5A–B). The speciﬁcity of MβC was
proved by adding exogenous cholesterol, which canceled its effect
(Fig. 5B). The involvement of clathrin-dependent endocytosis was cor-
roborated by siRNA-mediated targeting knock-down of its expression
(Fig. 5B). In contrast to the results observed in PLC-PRF-5, in Hep3B
cells neither dynasore nor MβC were able to prevent the SDF-1α-
induced internalization of CXCR4 (Fig. 5C–D). We checked the efﬁ-
ciency of dynasore in inhibiting endocytosis in Hep3B cells by mea-
suring the internalization of transferrin, a marker of clathrin-
mediated endocytosis [36]. As expected, dynasore inhibited transfer-
rin internalization in both PLC/PRF/5 and Hep3B cells (Suppl. Fig. S6).
This prompted us to investigate alternative paths for CXCR4 internal-
ization in Hep3B cells.
Fig. 3. CXCR4 requires the exocyst complex to be transported to the plasmamembrane in PLC/PRF/5 cells. A. Representative confocal images of PLC/PRF/5 cells expressing the CXCR4–EGFP
chimera (upper left panel), their stainingwith anti-EXOC4 (lower left panel), and the colocalization of both signals (yellow pixels at the upper right panel). Arrows point to the presence of
CXCR4–EGFP and EXOC4 in the cell-to-cell junction of the EGFP–CXCR4 expressing cells. The three small lower right panels are orthogonal XZ sections for the red, green and merge
channels of the two cells expressing EGFP–CXCR4, extracted at the level of the white bar of the upper right panel. The main panels show single confocal images at a medium focal
plane. Scale bar is 20 μm. B. Western blotting analysis of PLC/PRF/5 cells treated with an EXOC4-targeting siRNA (siEXOC4) or with a control siRNA (siScrambled). β-Actin shown as a
loading control. Left: a representative experiment is shown; right: mean ± SD of the densitometric analysis of four independent experiments, expressed as relative to β-actin levels. C.
Flow cytometric analysis of sCXCR4 levels in PLC/PRF/5 cells treated with either a scrambled siRNA or a speciﬁc EXOC4 siRNA. Left. A representative plot. Right. Quantitative analysis,
expressed as mean ± SD of three different experiments. (*p b 0.05, Student's t test).
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by macropinocytosis. Therefore, we treated Hep3B cells with
dimethylamiloride (DMA), which is an inhibitor of this internalizationpathway [37]. As shown in Fig. 6, cells pretreated with 100 μM DMA
inhibited the ligand-induced internalization of CXCR4 in Hep3B, which
demonstrates a signiﬁcant role ofmacropinocytosis in the internalization
Fig. 4. CXCR4–EGFP and EXOC4 colocalize at the plasma membrane in Hep3B cells. A. Representative confocal images of individualized Hep3B cells expressing the CXCR4–EGFP chimera
(upper left panel), their staining with anti-EXOC4 (upper right panel), and the colocalization of both signals (yellow pixels at the lower left panel). The central cell showing CXCR4–EGFP
and EXOC4 labels is magniﬁed at the lower right panel. Arrows in the upper panels point to the presence of CXCR4–EGFP and EXOC4 in the membranes of Hep3B cells, as well as the ar-
rowheads in the magniﬁed panel. The yellow arrow in the magniﬁed panel shows two vesicles, at the tip of a membrane projection, in which CXCR4–EGFP and EXOC4 can be detected
together. The white line of the upper left panel draws the perimeter of the Hep3B cell. Shown are single confocal images at a medium focal plane. Scale bar is 20 μm. B. Representative
confocal images of a group ofHep3B cells expressing theCXCR4–EGFP chimera (upper left panel), their stainingwith anti-EXOC4 (upper right panel), and the co-localization of both signals
(yellow pixels at the lower panel). Arrowheads show sites of CXCR4–EGFP and EXOC4 colocalization at the cell-to cell junction,while the arrowhead at the upper left panel shows CXCR4–
EGFP at the plasma membrane in the absence of cell-to-cell contact. Shown is the max. projection of three consecutive confocal images at a medium focal plane. Scale bar is 20 μm.
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effect on CXCR4 trafﬁcking in SDF-1α-treated Hep3B cells, we analyzed
the effect of DMA on the trafﬁcking of another cell surface receptor, the
Epidermal Growth Factor Receptor (EGFR). The exposition of this recep-
tor at the cell surface did not change by the treatment with DMA, neither
in untreated nor in SDF-1α-treated cells (Suppl. Fig. S7). DMA did not
show any signiﬁcant inhibitory effect on SDF-1α-mediated CXCR4 endo-
cytosis in PLC/PRF/5 cells (data not shown).Finally, we studied the fate of internalized CXCR4. Internalized re-
ceptors can be either transported to lysosomal degradation or exported
back to the plasma membrane through recycling endosomes. We
stained CXCR4–EGFP-transfected PLC/PRF/5 and Hep3B cells for
Rab11, a suggested marker of recycling endosomes [38]. CXCR4–EGFP
colocalized with Rab11+ in the absence of ligand, in both HCC cell
lines examined (Fig. 7, arrows). Furthermore, this localization of
CXCR4–EGFP in Rab11+ vesicles was not due to an autocrine secretion
Fig. 5. Endocytosis of CXCR4 in SDF-1α-treated PLC/PRF/5 and Hep3B cells. Effect of the endocytosis inhibitors MβC and dynasore. A and C. Flow cytometry plots showing sCXCR4 in PLC/
PRF/5 (A, upper-left panel) andHep3B (C, upper-left panel) cells, its internalization upon ligand binding (100 ng/mL SDF-1α treatment during 8 h, upper-right panels), aswell as the effect
caused by preincubation with MβC (2.5 μM, lower-left panels) and dynasore (dyn, at 80 μM, lower-right panels). A representative plot of three different experiments is shown. B and D.
Quantitative analysis of the decrease in sCXCR4 after SDF-1α treatment in PLC/PRF/5 (B) and Hep3B cells (D), and how pretreatment with MβC or dynasore interferes in this effect. Also
shown are the recovery effect of cholesterol on SDF-1α-mediated endocytosis after MβC treatment (MβC + Chol + SDF-1α), and the blockade of internalization after incubation with a
clathrin-speciﬁc siRNA (siRNA Clathrin + SDF-1α), as complementary experiments for the two pathways studied. Results are mean ± SD of three independent experiments. Statistical
analysis: *p b 0.05, ***p b 0.001: values referred to each respective control (no SDF-1α treatment) and data analyzed by using the Student's t test; #p b 0.05, ##p b 0.01: values referred
to the SDF-1α treated cells and data analyzed by Tukey's one-way ANOVA test.
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SDF-1α antagonist AMD3100 showed highly similar staining pattern
of CXCR4–EGFP/Rab11 distribution. Finally, CXCR4–EGFP and Rab11
also colocalized in cells treated with SDF-1α. Some of these vesicles
could also be visualized in Hep3B cells treated with AMD3100 (Fig. 7,
arrowheads), a particularly interesting ﬁnding since Hep3B cells, as
demonstrated above, used macropinocytosis to internalize CXCR4.
These results indicate that despite the use of different endocytic mecha-
nisms both HCC cells may use common intracellular trafﬁcking hubs (asRab11+ endosomal bodies) for receptor sorting.We also studiedwheth-
er CXCR4 travels through Rab4+ (early endosomes marker) or Rab5+
(late endosomes marker). Co-localization of CXCR4–EGFP with Rab4+
compartment was observed in untreated PLC/PRF/5 cells and increased
after SDF-1α treatment (Suppl. Fig. S8). Similar results were obtained
for Rab5+ (data not shown). In Hep3B cells, much less colocalization of
CXCR4–EGFP with Rab4+ or Rab5+ vesicular compartments were ob-
served when compared with that in PLC/PRF/5 cells (Suppl. Fig. S8 and
data not shown). This result suggests that after SDF-1α treatment, the
Fig. 6. CXCR4 is internalized by macropinocytosis in SDF-1α-treated Hep3B cells A. Flow cytometric analysis of sCXCR4 in Hep3B cells and its internalization upon ligand binding
(100 ng/mL SDF-1α treatment during 8 h). B. Prevention of SDF-1α-induced internalization of CXCR4 by preincubation of cells with 100 μM DMA. A and B show representative plots
of three independent experiments. C. Quantitative analysis as mean ± SD of the different experiments. Statistical analysis: ***p b 0.001: value referred to control untreated cells (no sig-
niﬁcant differences were observed when treatment with DMA + SDF-1αwas compared with DMA-treated or untreated cells); #p b 0.05: values referred to the SDF-1α treated cells. In
both cases, data were analyzed by using the Student's t test.
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expected taking into account their different response to inhibitors of
the caveolin- and clathrin-dependent endocytic pathways.
Rab 11 is not restricted to the recycling endosome, but it is also at the
trans-Golgi network (TGN) [39] and at post-Golgi vesicles [40]. To
understand the role of Rab11 in the regulation of CXCR4 trafﬁcking,
PLC/PRF/5 cells were treated with brefeldin A (BFA), which disrupts
the Golgi and consequently inhibits secretory protein transport. As
shown in Fig. 8A, in untreated PLC/PRF/5 cells, CXCR4–EGFP localized
at cell-to-cell junctions (upper left panel, arrows) and in intracellular
membrane compartments. Proﬁle of the intensity of CXCR4 and Rab11
staining values of pixels along the line drawn at the insert area of the
merge panel demonstrated a high degree of colocalization (Fig. 8A,lower right). BFA treatment disrupted the Golgi-like staining pattern
of CXCR4–EGFP (Fig. 8B, upper left panel) and the pericentriolar
Rab11 staining (Fig. 8B, upper right panel). Moreover, BFA attenuated
the presence of CXCR4 at the cell surface. The clear difference in the
pixel intensity proﬁles of CXCR4 and Rab11 immunostainings suggests
that BFA reduced the formation of Rab11+/CXCR4+ vesicles. Altogether,
these results indicate that Rab11+ endosomes also participate in the
post-Golgi delivery of CXCR4–EGFP to the cell surface.
4. Discussion
The CXCR4/SDF-1α axis is a key regulator of cancer and metastasis
[7]. We have investigated the dynamics of CXCR4 expression in
Fig. 7. EGFP–CXCR4 accumulates in Rab11+ recycling endosomes in PLC/PRF/5 andHep3B cells. Representative confocal images of PLC/PRF/5 andHep3B cells expressing the CXCR4–EGFP
chimera (left panel), their staining with anti-Rab11 (central panel), and the co-localization of both signals (yellow pixels at the right panel). Cells were untreated or treatedwith the SDF-
1α antagonist AMD3100 (1 μg/mL) or SDF-1α (100 ng/mL) during 8 h. Arrows show colocalization of CXCR4–EGFP and Rab11. Arrowheads show CXCR4–EGFP positive/Rab11 negative
vesicles and the green arrowheads thepresenceof EGFP–CXCR4 at a cell–cell junction. Shown is the averageprojection of three consecutive confocal sections at amedium focal plane. Scale
bar is 20 μm.
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export and maintenance of cell surface CXCR4 in Hep3B and in PLC/
PRF/5 cells. Expression of CXCR4 was studied by ﬂow cytometry in
alive and in permeabilized cells, and by ﬂuorescence microscopy in
CXCR4–EGFP transfectants or in cells stained for endogenous CXCR4
(Fig. 1). In all the cases, we detected CXCR4 in the surface of live cells,
but, much interestingly, we also found signiﬁcant amounts of CXCR4
in intracellular vesicular deposits in both cell lines, which appears to
be independent of autocrine SDF-1α-mediated intracellular trafﬁcking
(Suppl. Fig. S2).
This cytoplasmic enrichment of CXCR4 has been already described in
B-lymphocytes [41], peripheral blood lymphocytes [42] and CD34+
hematopoietic progenitors transduced with a CXCR4–EGFP construct,
in which CXCR4-rich cytoplasmic vesicles were detected colocalizingwith endosomal markers EEA-1, Rab4, Rab5 and Rab11 [24]. Similarly,
cytoplasmic trapping of CXCR4 was also described for some HCC lines,
although no data were made available on the subcellular structures
involved [43]. Here, we have shown that CXCR4 intracellular deposits
in Hep3B and in PLC/PRF/5 cells presented a perinuclear pattern of
subcellular localization (Fig. 2) compatible with the Golgi apparatus.
Confocal colocalization experiments with β-COP, GM130, golgin 97,
and M6PR conﬁrmed that CXCR4 was mostly stored in the vesicles of
the Golgi apparatus of PLC/PRF/5 and Hep3B cells (Fig. 2, and Suppl.
Fig. S4), while further colocalization with AP1 suggests that CXCR4 traf-
ﬁcked through the Golgi/AP1 system to reach the plasmamembrane. In
this sense, and despite showing similar intracellular deposits of CXCR4,
PLC/PRF/5 and Hep3B cells greatly differed in sCXCR4 expression. All
Hep3B cells showed CXCR4 at the cell surface and a percentage of
Fig. 8. Brefeldin A treatment impairs exportation of CXCR4–EGFP to cell–cell junctions at the plasmamembrane. A. Representative confocal images of untreated PLC/PRF/5 cells expressing
the CXCR4–EGFP chimera (upper left panel), their staining with anti-Rab11 (upper right panel) and the colocalization of both signals (yellow pixels at the lower left panel). The proﬁle of
pixel intensity along the white line drawn in the insert (lower left) is presented in the lower right panel. Arrows indicate the presence of EGFP–CXCR4 at cell surface (cell–cell junctions),
and arrowheads indicate Rab11+ patches. B. As in A, but after treating cells with 10 μg/mL brefeldin A during 3 h. Both A and B show single confocal sections at a medium focal plane. The
proﬁles of pixel intensity were performed on the max. projections of ﬁve consecutive confocal sections (see insert boxes) at a medium focal plane. Scale bars are 20 μm.
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measured in PLC/PRF/5 cells. The high levels of sCXCR4 in Hep3B cells
were, furthermore, dependent on TGF-β signaling, since silencing of
the TβRI caused a signiﬁcant reduction of sCXCR4 in the Hep3B cells,
but not in PLC/PRF/5 cells (Suppl. Fig. S3). SinceHep3B cells showhigherautocrine production of TGF-β than PLC/PRF/5 cells [31], results here
shown highlight the cross-talk between the TGF-β and the SDF-1α/
CXCR4 pathways in HCC cells.
The presence of CXCR4 trapped in the cell cytoplasm could be
physiologically relevant. Intracellular CXCR4 could represent a pool of
1216 E.B. Cepeda et al. / Biochimica et Biophysica Acta 1853 (2015) 1205–1218receptor to be mobilized to the plasmamembrane, thus establishing an
additional regulatory point for mechanisms controlling CXCR4 export
and activation. Alternatively, it could reﬂect the need for additional
co-transporters that facilitate its trafﬁcking to the plasma membrane.
In this sense, CXCR4 has been detected in the endoplasmic reticulum
after the expression of mutated forms of SDF-1α which included a
KDEL-ER retention sequence. KDEL-tagged SDF-1α would retain
CXCR4 in the ER, targeting the complex for degradation, with the subse-
quent decrease in sCXCR4 [44], and impairment of the migratory [45]
and metastatic [46] potentials of the affected cells. Furthermore, trans-
fection of the membrane tetraspanin CD63, as well as of an N-terminal
deletion mutant, was shown to suppress sCXCR4 by redirecting CXCR4
intracellular trafﬁc to endosomal bodies [14]. On the contrary, overex-
pression of CCR5, another chemokine receptor that associates to
CXCR4 in the plasmamembrane of Jurkat T-cells [47], was shown to fa-
cilitate the intracellular trafﬁc of CXCR4, which resulted in increased
levels of sCXCR4 [48,49].
We have previously shown that HCC cells expressed sCXCR4 in an
asymmetric, polarized, way [30,31]. This is highly relevant because
upon epithelial-to-mesenchymal transition, apical–basal polarity
should be replaced or complemented with the establishment of a
front-rear polarity axis that placed guidance receptors at the leading
edge of cells to allow for directed migration, in a complex process that
requires the reorientation of membrane trafﬁcking pathways ([50,51]
for reviews). One of the main mechanisms of vesicle trafﬁcking and
tethering to the plasma membrane involves the activity of the evolu-
tionarily conserved exocyst, and here, we have demonstrated that
trafﬁcking of CXCR4 to the plasma membrane is dependent on this
complex. We ﬁrst detected co-localization of CXCR4–EGFP and EXOC4
(an exocyst complex subunit) at the cell-to-cell junctions at the lateral
membrane of PLC/PRF/5 (Fig. 3) and Hep3B cells (Fig. 4), as well as at
the tip of a membrane projection of a Hep3B cell (Fig. 4A, insert). In
this regard, it has been shown that the exocyst complex speciﬁcally
targets the lateral membrane of polarized epithelial cells [52], and that
its subcellular localization changes according the development of
membrane polarity, associated to the trans-Golgi network in cells with
non-polarized membranes [53], localized in cell-to-cell contacts when
these are established and restricted to the lateral/apical border in fully
polarized cells [52]. The fact that CXCR4 is targeted to the lateral
membrane via the exocyst complex set interesting questions on the
establishment of the front-rear polarity axis, required for guided cell
migration, and the mechanisms regulating the shift of CXCR4 from the
lateral domain to the leading edge of the cell front. Work is in progress
to study this intriguing topic. Finally, the functional involvement of the
exocyst complex in the targeted trafﬁc of CXCR4was fully demonstrated
by scoring a signiﬁcant reduction of sCXCR4 in PLC/PRF/5 cells in which
EXOC4 had been siRNA knocked-down, when compared with cells
treated with the scrambled control (Fig. 3).
CXCR4 is internalized upon incubation with SDF-1α in both PLC/
PRF/5 and in Hep3B cells. This result is in agreement with previous
works which demonstrated ligand-dependent [17] and independent
[54] down-modulations of sCXCR4 in CXCR4-transfected epithelial
My-1-lu and HeLa cells, respectively. CXCR4 internalization could be
reversed by coexpressing dominant negative mutants of dynamin-1
and arrestin-3 [20], a fact pointing out to the involvement of clathrin-
mediated mechanisms in the endocytosis process. Interestingly,
PLC/PRF/5 and Hep3B cells showed a different behavior regarding
CXCR4 internalization. In PLC/PRF/5 cells CXCR4 internalization was
blocked by endocytosis inhibitors, such as dynasore and MβC (Fig. 5).
Hep3B cells were resistant to the action of these inhibitors and CXCR4
internalization was blocked by DMA, an inhibitor of macropinocytosis
[37] that speciﬁcally blocks SDF-1α induced internalization of CXCR4
(Fig. 6), but not other membrane receptors (Suppl. Fig. S7), in Hep3B
cells. This is an endocytic mechanism suited to the internalization of
large volumes of extracellular components, viruses, pathogens etc.,
and usually activated by the triggering of growth factor receptors (see[55] for a review). Macropinocytosis has been considered to play an
important role in stimulating nutrient uptake in cancer cells [56],
establishing chemotactic responses in highly motile cells as neutrophils
[57], and to modulate cell locomotion through modiﬁcation of
endocytic membrane trafﬁc [58,59].
Finally, following internalized CXCR4 through different endosomal
compartments, we observed in PLC/PRF/5 cells the presence of
CXCR4–EGFP in Rab11+, Rab4+ and Rab5+ membrane compartments,
whereas in Hep3B cells CXCR4 mainly colocalized with Rab11 (Fig. 7
and Suppl. Fig. S8). This latter might indicate that macropinocytic-
associated vesicles are used not only for the entrance of CXCR4, but
sorting endosomes to its recycling to the plasma membrane too. A
similar result has been recently described for the internal redistribution
of integrins during the PDGF-induced migration of ﬁbroblasts [60] and
suggests that this could be a common mechanism of receptor sorting
used by motile cells. However, here we also show that BFA decreased
the presence of Rab11+ patches and attenuated membrane location of
CXCR4–EGFP in PLC/PRF/5 cells. Furthermore, pixel-proﬁling on
confocal projections showed that a subpopulation or Rab11+ patches
were mostly depleted of CXCR4–EGFP (Fig. 8), which could correspond
to the trans-Golgi-associated secretory transport, whereas other
population of intracellular vesicles maintain CXCR4, which could reﬂect
recycling endosomes. These results suggest a post-Golgi transport of
CXCR4–EGFP through theRab11+endosomes. In support of this interpre-
tation, other plasma membrane proteins, such as E-cadherin, exit the
Golgi complex in pleomorphic tubulovesicular carriers, which, instead
ofmoving directly to the cell surface, usually fuse ﬁrst with an intermedi-
ate compartment, subsequently identiﬁed as a Rab11-positive recycling
endosome [61].
In conclusion, the results here described demonstrate that although
PLC/PRF/5 and Hep3B cells express CXCR4 at the cell surface (these last
ones at high levels), part of the CXCR4 is maintained in intracellular
deposits that colocalize with markers of the Golgi apparatus and of the
recycling endosome complex. We also demonstrate that PLC/PRF/5
and Hep3B cells use distinct mechanisms for the internalization of
CXCR4. Thus, whereas in PLC/PRF/5 cells, CXCR4 endocytosis relies on
dynamin-dependent mechanisms, in Hep3B macropinocytosis is the
main mechanism used for its internalization. Colocalization of CXCR4
with Rab11+, but not with Rab4+ or Rab5+ membrane compartments,
occurs in both type of cells. Attenuation of this colocalization when
Golgi is disrupted indicates that Rab11 would be also involved in the
post-Golgi transport of CXCR4 to the plasma membrane. Altogether,
this work reveals intracellular trafﬁcking pathways of CXCR4, whose
pharmacological targeting could result in the inactivation of one of the
mainmechanisms used bymetastatic cells to colonize secondary organs
and tissues.
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